Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

Methodist Jennie Edmundson Hospital Partners With Acadia Healthcare to Build New Behavioral Health Hospital in Council Bluffs: https://mms.businesswire.com/media/20200504005676/en/583255/5/ACHC.jpg
Methodist Jennie Edmundson Hospital Partners With Acadia Healthcare to Build New Behavioral Health Hospital in Council Bluffs


According to American Hospital Directory data, there is a shortfall of more than 300 inpatient behavioral health beds in Iowa and Nebraska.



To address this need, Methodist Jennie Edmundson

Acadia Healthcare Forms Joint Venture Partnership With Nebraska Methodist Health System: https://mms.businesswire.com/media/20200504005676/en/583255/5/ACHC.jpg
Acadia Healthcare Forms Joint Venture Partnership With Nebraska Methodist Health System


Acadia Healthcare Company, Inc. (NASDAQ: ACHC) announced today that it has formed a joint venture with Nebraska Methodist Health System to build a state-of-the-art, 96-bed behavioral health

QuidelOrtho Partners With BYG4lab® to Strengthen Informatics Offerings: https://s24.q4cdn.com/594651504/files/design/QO_Logo_FINAL.png
QuidelOrtho Partners With BYG4lab® to Strengthen Informatics Offerings


QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and

Convatec Group PLC: HOL-Holding(s) in Company
Convatec Group PLC: HOL-Holding(s) in Company
Convatec Group PLC: HOL-Holding(s) in Company
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Almirall’s H1 2023 Results: Almirall Achieves Net Sales Growth of 7% to €466.1MM, Driven by Strong Growth in European Dermatology Business: https://mms.businesswire.com/media/20221109006035/en/1631769/5/ALM_AW_LOGO_Tagline_MV_Positive_RGB_%281%29.jpg
Almirall’s H1 2023 Results: Almirall Achieves Net Sales Growth of 7% to €466.1MM, Driven by Strong Growth in European Dermatology Business


Almirall, S.A. (ALM), the global biopharmaceutical company based in Barcelona, has announced its H1 2023 financial results.



Financial highlights (€ rounded million)


 


H1 2023

 

Pfizer Announces Post-Tornado Relief Plans for Rocky Mount Community and Manufacturing Facilityhttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer Announces Post-Tornado Relief Plans for Rocky Mount Community and Manufacturing Facility


Pfizer Inc. (NYSE: PFE) today announced the company’s immediate efforts to provide relief and repair the damage caused to its manufacturing facility in Rocky Mount, North Carolina after a violent

Novocure Announces Favorable Independent Data Monitoring Committee Recommendation to Continue Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields Therapy in Pancreatic Cancer: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg
Novocure Announces Favorable Independent Data Monitoring Committee Recommendation to Continue Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields Therapy in Pancreatic Cancer


Novocure (NASDAQ: NVCR) today announced the results of a pre-specified interim analysis for the phase 3 PANOVA-3 clinical trial evaluating the safety and efficacy of Tumor Treating Fields

EQS-Adhoc: Eckert & Ziegler again achieves sales growth compared to the previous year and confirms its forecast for 2023. Decline in earnings compared to same period last year due to extraordinary items.
EQS-Adhoc: Eckert & Ziegler again achieves sales growth compared to the previous year and confirms its forecast for 2023. Decline in earnings compared to same period last year due to extraordinary items.
EQS-Adhoc: Eckert & Ziegler again achieves sales growth compared to the previous year and confirms its forecast for 2023. Decline in earnings compared to same period last year due to extraordinary items.
Owens & Minor Announces Second Quarter 2023 Earnings Release Date and Conference Call: https://mms.businesswire.com/media/20211103005246/en/922805/5/O%26M_LogoTM_hi-res.jpg
Owens & Minor Announces Second Quarter 2023 Earnings Release Date and Conference Call


Owens & Minor, Inc. (NYSE: OMI) plans to release financial results for the second quarter of 2023 on Friday, August 4, 2023, before trading begins on the New York Stock Exchange.



The Company

Sartorius Stedim Biotech SA: Information on Document Availability
Sartorius Stedim Biotech SA: Information on Document Availability
Sartorius Stedim Biotech SA: Information on Document Availability
EQS-Adhoc: BB Biotech AG publishes its interim report
EQS-Adhoc: BB Biotech AG publishes its interim report
EQS-Adhoc: BB Biotech AG publishes its interim report
EQS-News: BB BIOTECH AG: Sector rotation and fund outflows weigh on biotech stocks, but positive developments allow fund raising to strengthen industry
EQS-News: BB BIOTECH AG: Sector rotation and fund outflows weigh on biotech stocks, but positive developments allow fund raising to strengthen industry
EQS-News: BB BIOTECH AG: Sector rotation and fund outflows weigh on biotech stocks, but positive developments allow fund raising to strengthen industry
Sartorius Stedim Biotech SA: Half-year results 2023 of Sartorius Stedim Biotech
Sartorius Stedim Biotech SA: Half-year results 2023 of Sartorius Stedim Biotech
Sartorius Stedim Biotech SA: Half-year results 2023 of Sartorius Stedim Biotech
Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2023 Financial Results: https://mms.businesswire.com/media/20191106005906/en/305625/5/puma_logo_JPEG.jpg
Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2023 Financial Results


Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, August 3, 2023, following the release of its second

Sangamo Therapeutics and Chroma Medicine Announce Option and License Agreement to Evaluate and Develop Zinc Finger Proteins for Epigenetic Editing: https://mms.businesswire.com/media/20191101005100/en/736004/5/Sangamo_logoTM.jpg
Sangamo Therapeutics and Chroma Medicine Announce Option and License Agreement to Evaluate and Develop Zinc Finger Proteins for Epigenetic Editing


Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a clinical-stage genomic medicine company and Chroma Medicine, Inc. (Chroma), a genomic medicine company pioneering single-dose epigenetic editing

Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 3, 2023: https://mms.businesswire.com/media/20191107005278/en/707846/5/Aurinia-logo-web-700px.jpg
Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 3, 2023


Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for the second quarter of 2023, on Thursday, August 3

Pfizer Announces New England Journal of Medicine Publication on Group B Streptococcus (GBS) Maternal Vaccine Candidatehttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer Announces New England Journal of Medicine Publication on Group B Streptococcus (GBS) Maternal Vaccine Candidate


Pfizer Inc. (NYSE: PFE) today announced data from a Phase 2 study investigating its hexavalent capsular polysaccharide (CPS) conjugate Group B Streptococcus (GBS) vaccine candidate, GBS6, being

Premier, Inc. to Report Fiscal 2023 Fourth-Quarter and Full-Year Results and Host Conference Call on August 22, 2023: https://mms.businesswire.com/media/20191105005372/en/754182/5/PR_LogoSpec_%282%29.jpg
Premier, Inc. to Report Fiscal 2023 Fourth-Quarter and Full-Year Results and Host Conference Call on August 22, 2023


Premier, Inc. (NASDAQ: PINC) today announced that it will release financial results for its fiscal 2023 fourth quarter and full year on Tuesday, August 22, 2023, at approximately 6:30 a.m. ET. The

Agilent to Announce Third-Quarter Fiscal Year 2023 Financial Results Aug. 15Photo, wide shot, wide-angle lens, soft focus,  Reinsurance company, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by Sebastião Salgado: https://oaidalleapiprodscus.blob.core.windows.net/private/org-IbuNdCATsFaPOITjFOv2kJh3/user-AXaxqjBUW45D8BadJEo9mUpW/img-bSRc7PrRT00tZTDNf9SggMTD.png?st=2023-05-06T18%3A48%3A49Z&se=2023-05-06T20%3A48%3A49Z&sp=r&sv=2021-08-06&sr=b&rscd=inline&rsct=image/png&skoid=6aaadede-4fb3-4698-a8f6-684d7786b067&sktid=a48cca56-e6da-484e-a814-9c849652bcb3&skt=2023-05-06T00%3A38%3A49Z&ske=2023-05-07T00%3A38%3A49Z&sks=b&skv=2021-08-06&sig=3seGuy7NQJX9RXUOWr6XArANokWXlKqwnEJxEHfdbSY%3D
Agilent to Announce Third-Quarter Fiscal Year 2023 Financial Results Aug. 15


Agilent Technologies Inc. (NYSE: A) will release financial results for the third quarter of fiscal year 2023 after the stock market closes on Tuesday, Aug. 15. In addition, the company will host a

Long Term Phase 3 Data Published in Arthritis & Rheumatology Shows LUPKYNIS® (voclosporin) Preserved Kidney Function Up to Three Years in Lupus Nephritis Patients with No New or Unexpected Adverse Events: https://mms.businesswire.com/media/20191107005278/en/707846/5/Aurinia-logo-web-700px.jpg
Long Term Phase 3 Data Published in Arthritis & Rheumatology Shows LUPKYNIS® (voclosporin) Preserved Kidney Function Up to Three Years in Lupus Nephritis Patients with No New or Unexpected Adverse Events


Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that full results from the Phase 3, double-blind, placebo-controlled AURORA 2 extension study were published

Charles River Laboratories Schedules Second-Quarter 2023 Earnings Release and Conference Call: https://mms.businesswire.com/media/20191106005189/en/754630/5/charles_river_logo.jpg
Charles River Laboratories Schedules Second-Quarter 2023 Earnings Release and Conference Call


Charles River Laboratories International, Inc. (NYSE: CRL) will release second-quarter 2023 financial results on Wednesday, August 9th, before the market opens. A conference call has been scheduled

STAAR Surgical to Report Second Quarter Results on August 2, 2023: https://mms.businesswire.com/media/20200413005098/en/683092/5/STAAR_Surgical_Logo_Primary_Lockup_%28Sunise_Teal%29.jpg
STAAR Surgical to Report Second Quarter Results on August 2, 2023


STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, today announced that it will release financial results for the second

Sensorion Submits Clinical Trial Application for OTOF-GT, its Lead Gene Therapy Candidate, in Europe: https://mms.businesswire.com/media/20210609005851/en/705797/5/logo-sensorion2.jpg
Sensorion Submits Clinical Trial Application for OTOF-GT, its Lead Gene Therapy Candidate, in Europe


Regulatory News:



Sensorion (FR0012596468 – ALSEN) (Paris:ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and

Relief Therapeutics Announces Extension of Distribution Agreement for PKU GOLIKE® in the U.S. with Pentec Health
Relief Therapeutics Announces Extension of Distribution Agreement for PKU GOLIKE® in the U.S. with Pentec Health
Relief Therapeutics Announces Extension of Distribution Agreement for PKU GOLIKE® in the U.S. with Pentec Health